Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aurinia Pharmaceuticals Inc is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Aurinia Pharmaceuticals employs 294 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$12.48|
|52-week range||$9.72 - $18.60|
|50-day moving average||$12.50|
|200-day moving average||$13.39|
|Wall St. target price||$11.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.70|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||-1.96%|
|3 months (2021-05-03)||-0.64%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
|Revenue TTM||$51 million|
|Gross profit TTM||$-209,000|
|Return on assets TTM||-21.82%|
|Return on equity TTM||-40.13%|
|Market capitalisation||$1.8 billion|
TTM: trailing 12 months
There are currently 13.4 million Aurinia Pharmaceuticals shares held short by investors – that's known as Aurinia Pharmaceuticals's "short interest". This figure is 4% up from 12.8 million last month.
There are a few different ways that this level of interest in shorting Aurinia Pharmaceuticals shares can be evaluated.
Aurinia Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aurinia Pharmaceuticals shares currently shorted divided by the average quantity of Aurinia Pharmaceuticals shares traded daily (recently around 2.9 million). Aurinia Pharmaceuticals's SIR currently stands at 4.58. In other words for every 100,000 Aurinia Pharmaceuticals shares traded daily on the market, roughly 4580 shares are currently held short.
However Aurinia Pharmaceuticals's short interest can also be evaluated against the total number of Aurinia Pharmaceuticals shares, or, against the total number of tradable Aurinia Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aurinia Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Aurinia Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1086% of the tradable shares (for every 100,000 tradable Aurinia Pharmaceuticals shares, roughly 109 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aurinia Pharmaceuticals.
Find out more about how you can short Aurinia Pharmaceuticals stock.
We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.
Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.
Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $9.72 up to $18.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.3393. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).
Aurinia Pharmaceuticals Inc. , a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. , Ltd. The company is headquartered in Victoria, Canada. .
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.